pluripotent stem cell. However, the fact that not all CD34-positive or all BFU-E or CFU-GM colonies are positive for V617F suggests that the bone marrow of this patient is not monoclonal with respect to the JAK2 mutation.
In summary, the JAK2 V617F mutation was detected in a cohort of patients with 5qÀ syndrome and a hypercellular marrow. Despite no statistical difference, a higher median platelet count was observed in the mutant cases with 50% (3/6) showing a platelet count 4700 Â 10 9 /l compared with only 3% (3/91) in the wild-type cases. The lack of clinical response to erythropoietin in the two cases described fails to support previous in vitro studies documenting hypersensitivity to erythropoietin in the presence of the mutation.
Whether the JAK2 mutation occurs as an early or late event during the disease course is unclear. We detected the JAK2 mutation both at time of diagnosis and at a follow-up of 132 months in one case analysed, suggesting that the mutation occurred as an early event. Longer follow-up is however necessary to determine the prognostic significance of JAK2 mutation and in particular, whether these cases will show favourable response to lenalidomide as previously demonstrated in 5qÀ chromosomal abnormalities. In 1976, the French-American-British (FAB) Cooperative Group published a morphologic classification of acute myeloid leukemia (AML). 1 A revision of this classification published in 1985 was widely used and recognized as the standard for AML classification for over 15 years. 2 Included in the FAB classification were two groups of AML that exhibited monocytic differentiation, acute myelomonocytic leukemia (AMML; M4), and acute monoblastic/monocytic leukemia (AMoL; M5). A subset of M4 with abnormal and increased eosinophils (M4EO) was found to be associated with chromosome 16 abnormalities, either inv(16)(p13q22) or t(16;16)(p13;q22). Recognition of the biologic diversity within FAB AML subtypes led to the World Health Organization (WHO) classification of AML, published in 2001, in which morphologic, immunophenotypic, genetic, and clinical features of AML were included in defining disease entities.
3 By WHO criteria, cases previously diagnosed as FAB M4 or M5 may be classified as AML with recurrent cytogenetic abnormalities (inv(16)(p13q22)/t(16;16)(p13;q22)(CBFb/MYH11), 11q23(MLL), or t(8;21)(q22;q22)(AML1/ETO)), AML with multilineage dysplasia, therapy related AML, and AMML or AMoL subtypes of AML not otherwise categorized (NOC). Appropriate classification of AML is important for clinical management and allows for future studies to expand and refine our understanding of these diseases.
While immunophenotypic features are included in the WHO classification of AML, immunophenotypic criteria for monocytic Letters to the Editor AML have not been clearly defined. A high level of expression of CD14 is a specific feature of mature monocytes, but this antigen is frequently absent or underexpressed on immature monocytic cells. Furthermore, other antigens that are generally considered to be monocyte-associated may be expressed in other types of AML. The goals of the present study were to identify immunophenotypic patterns that reliably characterize monocytic AMLs and to explore their immunophenotypic heterogeneity in relationship to morphologic and cytogenetic subgroups.
A total of 126 cases of de novo AML diagnosed and analyzed with 4-color flow cytometry at our institution from 1998 to 2004 were included in the study. All cases were classified according to FAB criteria 2 based on morphology and cytochemical reactivity for myeloperoxidase and alpha naphthyl butyrate esterase (ANBE), and also according to WHO criteria 3 By flow cytometric analysis, blasts and monocytes were identified using CD45/side scatter (SSC)/forward scatter (FSC) characteristics in combination with various cell surface antigens. The frequency of antigen expression in 23 AMoLs was compared to 72 nonmonocytic AMLs (NM-AML) (Figure 1) . Overall, the blasts in AMoL more frequently expressed CD4, CD11b, CD14, CD16, CD36, CD56, CD64, and HLA-DR, and less often expressed CD34 compared to NM-AMLs (each Po0.01). As single markers, none of these were sufficiently sensitive and specific for identifying monocytic AML. CD14 expression in the blast/immature monocytic population was seen in all eight cases of acute monocytic leukemia, but in eight of 15 cases of acute monoblastic leukemia (P ¼ 0.021). There was no difference in expression of other monocyte-associated antigens between cases of acute monocytic leukemia and acute monoblastic leukemia. When the expression patterns of multiple antigens were explored, coexpression of CD36/FITC and CD64/ PE in blasts (Figure 2a ) was found in 22 (96%) of 23 cases of AMoL, but in only six (8%) of 72 cases of NM-AML (Po0.001). CD36 was expressed in both mature and immature monocytic cells, making it a useful marker of monocytic differentiation in immature monocytes that lack CD14 expression. All six cases of NM-AML with CD36/CD64 coexpression demonstrated a recurrent cytogenetic abnormality: t(8;21) in two cases, t(16;16) in one case, and t(15;17) (acute promyelocytic leukemia; APL) in three cases. Of note, each of the three cases containing the t(15;17) with coexpression of CD36 and CD64 showed microgranular features, a variant of APL that may be confused morphologically with acute monocytic leukemia.
However, all AMoLs in our series were positive for CD11b and HLA-DR, while none of the APLs expressed both antigens (data not shown). Furthermore, intense myeloperoxidase expression, either by cytochemistry or flow cytometry, should help to distinguish microgranular APL from AMoL.
Cases of FAB M4 AML could be divided into two groups based on the definitive separation of discrete subpopulation of blasts and monocytic cells in the analysis of CD45 and light scatter (Figure 2b and c) . One group showed a single (indistinguishable) population composed of both blasts and monocytic cells (designated group 1; 11 cases) (Figure 2b) . The immature cells in all cases of group 1 coexpressed CD36 and CD64. Thus, immunophenotypically, these closely resembled the AMoLs in our series, but were distinguished by a substantial population of maturing granulocytes. Although discrete population of blasts and monocytic cells could not be discriminated in these cases based on CD45 and light scatters, a continuous maturation spectrum could be appreciated in a CD36/CD45 dot plot (Figure 2b ). In the other group (group 2; 20 cases), there were distinct populations of blasts and monocytes (Figure 2c) . The immunophenotypically defined blasts in 15 of the 20 cases lacked the coexpression pattern of CD36 and CD64. However, all of these cases demonstrated a large proportion of monocytes, comprising 10-42% of all events (mean 24%).
We have recently shown that monocytic cells from cases of chronic myelomonocytic leukemia (CMML) bear multiple immunophenotypic aberrancies, including under-expression of CD13, CD15, CD36, or HLA-DR, and aberrant expression of CD2 or CD56. 4 In a similar fashion, we evaluated the monocytic cells from group 2 AMML cases. They also exhibited an aberrant immunophenotype in 16 (80%) of 20 cases. The aberrancies included underexpression of CD13 (3), CD36 (2), or HLA-DR (13), and aberrant expression of CD2 (7), CD5 (1), or CD56(1) Table 1 Comparison of monocyte aberrancies in cases of group 2 acute myelomonocytic leukemia with inv(16)/t(16;16) (M4EO) to those without the translocations (M4)
Cases
Aberrancies Aberrant immunophenotypes Letters to the Editor (Table 1) . Thus, significant immunophenotypic aberrancy in the context of monocytosis appears to be consistent with a monocytic neoplasm, and is a helpful feature in the diagnosis of borderline cases. The findings in the present study further indicate that even when a blast population lacks definitive immunophenotypic evidence of monocytic differentiation, the presence of a large number of aberrant monocytes suggests a monocytic AML.
All seven cases of AML with inv(16)/t(16;16) belonged to group 2 AMML, in that they had distinct populations of blasts and monocytes. Interestingly, the monocytic cells in this subgroup exhibited immunophenotypic abnormalities that distinguished them from other group 2 AMMLs lacking chromosome 16 abnormalities (Table 1) . They more frequently showed two or more monocyte aberrancies (6/7 vs 3/13; P ¼ 0.003). Specifically, CD2 expression in monocytes was identified in 6/6 cases with inv(16)(p13;q22), and was significantly correlated with chromosome 16 abnormalities among AMMLs (6/6 vs 1/11; P ¼ 0.001). The single case of AMML with t(16;16) that exhibited one monocyte aberrancy was not assessed for CD2 expression due to the absence of anti-CD2 in the panel (Table 1 ). An association between CD2 expression in the blast population of AML and inv(16) was documented in a prior study. 5 However, that 2-color flow cytometry study used gating techniques based purely on light scatter properties and probably could not distinguish a pure population of blasts versus some contaminating monocytes and lymphocytes. In the present study, CD2 was also detected on the blast population (as distinguished from the monocyte population) in four of six AMMLs with inv(16)/t(16;16). The blasts of NM-AML, in particular microgranular APL may also express CD2, 6 thus, this finding alone lacks specificity.
We found that all 11 cases of AMLs with 11q23 rearrangements in this series fell into the FAB M4 or M5 categories: nine AMoLs (eight monoblastic and 1 monocytic) and two AMMLs. Blasts in 10 of the 11 cases coexpressed CD36 and CD64; the remaining one was a group 2 AMML with 25% aberrant monocytes. In agreement with previous studies, no immunophenotypic features (other than monocytic differentiation) predicted the presence of an 11q23 rearrangement. 7 In summary, blasts of AMoL can be identified by coexpression of CD36 and CD64 with 96% sensitivity. Blasts of also AMML group 1 are CD36/CD64 positive. Therefore, it should be searched for more differentiated cells in order to separate AMML from AMoL when making the diagnosis upon immunological results. The coexpression pattern is seen in a small proportion of non-monocytic AMLs, including microgranular APL. This could be a potential diagnostic pitfall and requires correlation with other immunophenotypic features, cytomorphology, and cytogenetics. Furthermore, a well-defined population of monocytes (distinct from blasts) showing two or more aberrancies and CD2 expression was seen in all cases of AML with inv(16)(p13q22) and was 91% specific for this cytogenetic subgroup. Thus, in the context of AML, the presence of a distinct monocytic population with this unique immunophenotype should prompt evaluation for CBFb rearrangement.
Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia Chronic neutrophilic leukaemia (CNL) is a rare haematological disease of uncertain pathological aetiology. It has been recently defined as a chronic myeloproliferative disorder (CMPD) under the World Health Organization (WHO) classification, and is characterized by a persistent neutrophilia, splenomegaly and bone marrow (BM) hyperplasia. 1 Chronic neutrophilic leukaemia is of essence a diagnosis of exclusion, and affected patients have to be distinguished from other CMPD, such as chronic myelogenous leukaemia (CML), chronic myelomonocytic leukaemia and atypical CML. Causes of reactive neutrophilia need to be ruled out, and there should be no cytogenetic or molecular presence of the Philadelphia chromosome.
In the absence of a defining biological or molecular characteristic, the diagnosis of CNL is often challenging, and there have been approximately 150 reported cases in the literature. The overall outcome of these patients is poor, with the
